<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512461393</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512461393</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Topical Review</subject></subj-group></article-categories>
<title-group>
<article-title>Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know!</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Alkhawajah</surname><given-names>Mona M</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512461393">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Caminero</surname><given-names>Ana B</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512461393">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Freeman</surname><given-names>Hugh J</given-names></name>
<xref ref-type="aff" rid="aff3-1352458512461393">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Oger</surname><given-names>Joel JF</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512461393">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512461393"><label>1</label>Multiple Sclerosis Clinic, University of British Columbia Hospital, Canada</aff>
<aff id="aff2-1352458512461393"><label>2</label>Multiple Sclerosis Unit, Complejo Asistencial de Avila, Spain</aff>
<aff id="aff3-1352458512461393"><label>3</label>Department of Medicine (Gastroenterology), University of British Columbia, Canada</aff>
<author-notes>
<corresp id="corresp1-1352458512461393">Mona Alkhawajah, Room S-163, University of British Columbia Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T 2H7, Canada. Email: <email>monamarwan@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>259</fpage>
<lpage>265</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>8</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Multiple sclerosis (MS) is a demyelinating disorder of the central nervous system (CNS) but the causes have not been defined. The disease process appears to involve interplay between environmental factors and certain susceptibility genes. It is likely that the identification of the exact etiological mechanisms will permit the development of preventive and curative treatments. Evaluation of several diseases found to be more often associated than by chance alone may reveal clues to the etiology of those disorders. An association between MS and inflammatory bowel diseases (IBD) was suggested by the observation of an increased incidence of IBD among MS patients. A problem in the interpretation of the data rests, in part, with the observation that abnormal findings in brain magnetic resonance imaging (MRI) may be reported as MS in IBD patients. Defining the limits between incidental MRI findings and findings compatible with MS has resulted in further exploration of this possible association.</p>
</abstract>
<kwd-group>
<kwd>Multiple sclerosis</kwd>
<kwd>white matter lesions</kwd>
<kwd>inflammatory bowel diseases</kwd>
<kwd>ulcerative colitis</kwd>
<kwd>Crohn’s disease</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458512461393" sec-type="intro">
<title>Introduction</title>
<p>The differential diagnosis of multiple sclerosis (MS) includes several conditions where T2 hyperintense lesions are found on magnetic resonance imaging (MRI) of the brain. It has become one of the main reasons for consulting MS neurologists to grapple with the difficulties arising from a radiologist’s report containing the wording “MRI findings compatible with demyelination”. It has become even more of a headache since, by analogy with clinically isolated syndromes (CIS), the wording “radiologically isolated syndrome” (RIS) was introduced.<sup><xref ref-type="bibr" rid="bibr1-1352458512461393">1</xref></sup> Interestingly, a number of other autoimmune-based “rheumatologic” disorders such as systemic lupus erythematosus (SLE), Sjögren’s syndrome, mixed connective tissue disorders and others can be accompanied by hyperintense T2 lesions quite “compatible with demyelination”. Pathological correlation with imaging studies in MS and these disorders has been limited and precise differentiation of vascular and demyelinating T2 lesions has been difficult. It makes for quite an extensive discussion to try and differentiate “de vivo” between the vascular or demyelinating nature of these T2 lesions. Even post-mortem studies are limited.<sup><xref ref-type="bibr" rid="bibr2-1352458512461393">2</xref>,<xref ref-type="bibr" rid="bibr3-1352458512461393">3</xref></sup> It is also interesting to note that when higher magnetic fields are used even more lesions can be detected,<sup><xref ref-type="bibr" rid="bibr4-1352458512461393">4</xref></sup> so it is conceivable that with the use of a 7 Tesla MRI, the traditional criteria of Barkhof, incorporated in the MacDonald 2010 diagnostic criteria for MS, may lose their discriminating power.</p>
<p>Similar to MRI imaging in “rheumatologic diseases”, many patients with IBD, including both Crohn’s disease (CD) and ulcerative colitis (UC), exhibit abnormal T2 signals in the white matter, accompanied or not by clinical symptoms, that can mimic MS. Furthermore, treatment of these forms of IBD with certain biological agents developed against specific immune determinants may trigger the appearance of some white matter lesions. Among these biological agents are those reported to worsen MS such as anti-TNF.<sup><xref ref-type="bibr" rid="bibr5-1352458512461393">5</xref>,<xref ref-type="bibr" rid="bibr6-1352458512461393">6</xref></sup></p>
<p>To add to the riddle, some studies have reported that some MS clinic populations have an unexpected number of patients who have both IBD and MS.<sup><xref ref-type="bibr" rid="bibr7-1352458512461393">7</xref></sup></p>
<p>This review examines the relationship between IBD and MS, and further focuses on the clinical interpretation of abnormalities seen on MRI of the brain in patients suffering from these diseases.</p>
</sec>
<sec id="section2-1352458512461393">
<title>Brain-gut interactions</title>
<p>The very large gut epithelium is the habitat for a huge number of bacteria.<sup><xref ref-type="bibr" rid="bibr8-1352458512461393">8</xref></sup> Molecular mimicry is believed to play a major role in the pathogenesis of autoimmune disorders, and mimics are frequent among the non-pathogenic gut bacteria.<sup><xref ref-type="bibr" rid="bibr9-1352458512461393">9</xref></sup> Interactions between the human and intra-luminal microbial organisms take place through the gut epithelium and contribute to the functions of the innate and adaptive immune systems. This interaction continuously modulates the human immune response during life.<sup><xref ref-type="bibr" rid="bibr10-1352458512461393">10</xref></sup></p>
<p>In MS, increased intestinal permeability (“leaky gut”) has been hypothesized to be one explanation for autoimmune pathogenetic responses. This may trigger an autoimmune response through a three-way molecular mimicry involving food antigens, infectious agents and self- antigens.<sup><xref ref-type="bibr" rid="bibr11-1352458512461393">11</xref></sup> “Leaky gut” was initially reported in four out of 20 MS patients.<sup><xref ref-type="bibr" rid="bibr12-1352458512461393">12</xref></sup> Interestingly, 15 out of these 20 patients also had high peripheral blood CD45R0+ B cells, a marker reported to correlate with increased intestinal permeability in patients with CD.</p>
<p>The effect of oral antibiotics on the severity of experimental autoimmune encephalomyelitis (EAE), the animal model of MS, and on an experimental colitis model for IBD further supports the role of gut commensal bacteria in the development of autoimmune diseases.<sup><xref ref-type="bibr" rid="bibr13-1352458512461393">13</xref>,<xref ref-type="bibr" rid="bibr14-1352458512461393">14</xref></sup> These observations together with the observed effects of selective colonization with certain bacteria on the development of inflammation are in favor of a strong influence of the gut bacteria on the immune system<sup><xref ref-type="bibr" rid="bibr10-1352458512461393">10</xref></sup> and suggest that disturbances in gut physiology can lead to autoimmune diseases, including those of the CNS. Inversely, it has been shown that the brain and spinal cord may modulate inflammation in IBD.<sup><xref ref-type="bibr" rid="bibr15-1352458512461393">15</xref>,<xref ref-type="bibr" rid="bibr16-1352458512461393">16</xref></sup></p>
</sec>
<sec id="section3-1352458512461393">
<title>Neurological and other extraintestinal manifestations of IBD</title>
<p>CD and UC are the two major types of IBD. Three main factors are thought to be involved in the development of chronic inflammation in IBD<sup><xref ref-type="bibr" rid="bibr17-1352458512461393">17</xref></sup>: a reaction to a persistent intestinal infection; a defective mucosal barrier to luminal antigens; and a dysregulation of the immune response to ubiquitous antigens in a host with genetically determined susceptibility.</p>
<p>These disorders, however, may both be considered systemic illnesses as many organs outside the gastrointestinal tract can be involved. Extraintestinal involvement can be classified into four groups:<sup><xref ref-type="bibr" rid="bibr18-1352458512461393">18</xref></sup> first, those directly due to the inflammatory process such as erythema nodosum, pyoderma gangrenosum, arthritis, iritis/uveitis, etc.; second, those related to intestinal dysfunction (malnutrition and vitamins deficiency, anaemia, osteopathy, etc.); third, those that represent side effects of IBD medical or surgical treatment (e.g. steroid therapy and other immunosuppressives or immunomodulators, infections, etc.); and finally, those linked to the concomitant expression of other autoimmune disorders (e.g. ankylosing spondylitis, primary sclerosing cholangitis, thyroid disease, MS, etc.). Reactive extraintestinal manifestations occur when the bowel disease is active, recur with relapses, and are successfully controlled with medical treatment of the underlying IBD.<sup><xref ref-type="bibr" rid="bibr19-1352458512461393">19</xref></sup></p>
<p>Neurological manifestations have been reported in up to 36% of patients with IBD,<sup><xref ref-type="bibr" rid="bibr20-1352458512461393">20</xref></sup> and up to 74% of patients with extraintestinal manifestations developed clinical neurological complications mostly within one to 10 years after the diagnosis of bowel disease: in 10% of patients, these occurred at the time of an exacerbation of the IBD.<sup><xref ref-type="bibr" rid="bibr21-1352458512461393">21</xref></sup> The neurological manifestations included arterial or venous thrombotic events, CNS vasculitis, sensorineural hearing loss, seizures, myelopathies, peripheral neuropathies, myopathies (non-specific, granulomatous, interstitial myositis, dermatomyositis) and myasthenia gravis.<sup><xref ref-type="bibr" rid="bibr21-1352458512461393">21</xref><xref ref-type="bibr" rid="bibr22-1352458512461393"/><xref ref-type="bibr" rid="bibr23-1352458512461393"/><xref ref-type="bibr" rid="bibr24-1352458512461393"/><xref ref-type="bibr" rid="bibr25-1352458512461393"/><xref ref-type="bibr" rid="bibr26-1352458512461393"/><xref ref-type="bibr" rid="bibr27-1352458512461393"/>–<xref ref-type="bibr" rid="bibr28-1352458512461393">28</xref></sup></p>
</sec>
<sec id="section4-1352458512461393">
<title>IBD and CNS white matter lesions (WML)</title>
<p>WML seen in patients with IBD can be asymptomatic, or symptomatic of either a monophasic illness or a recurrent disease. Without autopsy studies it has been difficult to identify their underlying pathology. In some patients the clinical syndrome is suggestive, if not typical, of a demyelinating disorder whether monophasic (e.g. acute disseminated encephalomyelitis) or recurring (e.g. relapsing–remitting MS (RRMS)).<sup><xref ref-type="bibr" rid="bibr29-1352458512461393">29</xref>,<xref ref-type="bibr" rid="bibr30-1352458512461393">30</xref></sup> It has been previously emphasized that a number of other disorders need to be excluded as a cause of WML including migraine, small vessel disease and vasculitis.<sup><xref ref-type="bibr" rid="bibr2-1352458512461393">2</xref>,<xref ref-type="bibr" rid="bibr3-1352458512461393">3</xref>,<xref ref-type="bibr" rid="bibr20-1352458512461393">20</xref>,<xref ref-type="bibr" rid="bibr31-1352458512461393">31</xref></sup> In these disorders “typical” imaging characteristics of MS, such as periventricular lesions and Dawson fingers, posterior fossa lesions, and black holes, are expected to be scarce or absent.</p>
<p>“Iatrogenic” WML have also been considered in IBD patients. An increasing number of immunosuppressive and immune-modulatory drugs are being prescribed for IBD patients, particularly those who fail with first line agents like sulfasalazine and 5-amino salicylic acid.<sup><xref ref-type="bibr" rid="bibr32-1352458512461393">32</xref>,<xref ref-type="bibr" rid="bibr33-1352458512461393">33</xref></sup> Several case reports have linked these treatments, including anti-tumor necrosis factor alpha (anti-TNF-α) agents, methotrexate and metronidazole,<sup><xref ref-type="bibr" rid="bibr34-1352458512461393">34</xref><xref ref-type="bibr" rid="bibr35-1352458512461393"/><xref ref-type="bibr" rid="bibr36-1352458512461393"/>–<xref ref-type="bibr" rid="bibr37-1352458512461393">37</xref></sup> to the development of WML on MRI, or even clinical MS. Evidence however is inconclusive and a lack of long-term follow up in many of these case reports prevents us from determining whether these patients developed monophasic or recurrent disease. One possible explanation is that biologic agents like anti-TNF-α perhaps increase the odds of developing a demyelinating disease in patients who are originally susceptible, or they may simply unmask latent/pre-clinical MS. In their studies on mice, Arnett et al. found that TNF-α might have an essential role in remyelination through its effect on oligodendrocytes.<sup><xref ref-type="bibr" rid="bibr38-1352458512461393">38</xref></sup></p>
<p>Alternatively, autoimmune diseases may cluster in patients and their families<sup><xref ref-type="bibr" rid="bibr39-1352458512461393">39</xref>,<xref ref-type="bibr" rid="bibr40-1352458512461393">40</xref></sup> although this is not a uniform phenomenon, and evidence is conflicting.<sup><xref ref-type="bibr" rid="bibr41-1352458512461393">41</xref></sup></p>
<p>Several reports suggest a temporal relationship between starting treatment with infliximab and the development of WML or MS, or with the worsening of MS.<sup><xref ref-type="bibr" rid="bibr34-1352458512461393">34</xref>,<xref ref-type="bibr" rid="bibr35-1352458512461393">35</xref>,<xref ref-type="bibr" rid="bibr42-1352458512461393">42</xref></sup> However, among 500 CD patients treated with infliximab in the Mayo clinic experience, only one patient developed lesions consistent with demyelination.<sup><xref ref-type="bibr" rid="bibr43-1352458512461393">43</xref></sup> Further, Andersen et al.<sup><xref ref-type="bibr" rid="bibr44-1352458512461393">44</xref></sup> did not find an increased risk of MS development in IBD patients who were treated with biological agents when compared to those who were treated with non-biological agents. Indeed, a definite causal relationship based on currently available evidence is difficult to establish: however, caution continues to be advised when prescribing these drugs in IBD, and treated patients should be counseled and closely monitored for the development of neurological symptoms and MRI abnormalities.</p>
</sec>
<sec id="section5-1352458512461393">
<title>WML of undetermined significance</title>
<p>WML can be seen in neurologically asymptomatic IBD patients. They are usually few in number, small in size and non-enhancing.<sup><xref ref-type="bibr" rid="bibr45-1352458512461393">45</xref>,<xref ref-type="bibr" rid="bibr46-1352458512461393">46</xref></sup> Geissler et al.<sup><xref ref-type="bibr" rid="bibr45-1352458512461393">45</xref></sup> found WML (2–8 mm) in almost 50% of patients with IBD compared to only 16% of 50 healthy volunteers. Similarly, Hart et al.<sup><xref ref-type="bibr" rid="bibr46-1352458512461393">46</xref></sup> revealed WML (1–2 mm) in about 12% of IBD patients compared to 5% of controls. In both studies, most of the patients only had single WML. More recently, Chan et al.<sup><xref ref-type="bibr" rid="bibr47-1352458512461393">47</xref></sup> reported an impressive percentage of WML (72%) in neurologically asymptomatic individuals with CD (only 34% of age-matched controls), around 51% of them fulfilling Barkhof’s MS criteria. Importantly, none of these patients had black holes, Dawson’s fingers or gadolinium enhancement. The significance of incidentally discovered WML in individuals both with and without IBD is as yet undefined since some patients will remain asymptomatic at follow up, even those who have lesions fulfilling MS MRI diagnostic criteria, such as those of Barkhof.<sup><xref ref-type="bibr" rid="bibr48-1352458512461393">48</xref></sup></p>
<p>Most recently Barkhof et al. (personal communication, December 2011) looked at incidental white matter changes in a cohort of 960 CD patients; those were treated with natalizumab, and MRI scans were done for evaluation of the risk of progressive multifocal leukoencephalopathy (PML). None of them had PML and only four of the 960 patients (0.4%) had white matter changes which fulfilled the criteria for MS. All were neurologically asymptomatic. However, 43.9% of the CD patients had white matter changes, and one wonders how many of those would have been called “compatible with MS” by radiologists less astute and trained than Barkhof et al (<xref ref-type="fig" rid="fig1-1352458512461393">Figures 1</xref> and <xref ref-type="fig" rid="fig2-1352458512461393">2</xref>).</p>
<fig id="fig1-1352458512461393" position="float">
<label>Figure 1.</label>
<caption>
<p>Axial T2 fluid attenuated inversion recovery (FLAIR) for a patient with inflammatory bowel disease (IBD) and seizures (Medical Clinic, University of British Columbia (UBC) Hospital).</p>
</caption>
<graphic xlink:href="10.1177_1352458512461393-fig1.tif"/></fig>
<fig id="fig2-1352458512461393" position="float">
<label>Figure 2.</label>
<caption>
<p>Axial T2 FLAIR for a patient with inflammatory bowel disease (IBD) and clinically definite multiple sclerosis (MS) (MS Clinic, University of British Columbia (UBC) Hospital).</p>
</caption>
<graphic xlink:href="10.1177_1352458512461393-fig2.tif"/></fig>
</sec>
<sec id="section6-1352458512461393">
<title>MS and IBD: extent of association</title>
<p>An association between IBD and MS was first reported in 1982.<sup><xref ref-type="bibr" rid="bibr49-1352458512461393">49</xref></sup> Ten women with UC were found to have MS out of a total of 2261 patients. In our MS clinic at the UBC, Sadovnick et al. reported the co-occurrence of MS and IBD in four out of 748 MS patients, as well as 27 instances of familial concurrence of both diseases.<sup><xref ref-type="bibr" rid="bibr7-1352458512461393">7</xref></sup></p>
<p>In their retrospective study, Kimura et al.<sup><xref ref-type="bibr" rid="bibr50-1352458512461393">50</xref></sup> demonstrated an increased incidence of MS in a cohort of IBD patients from Olmsted County, Minnesota, USA. Four out of 474 IBD patients developed MS. In addition, 32 patients with both diagnoses referred to the Mayo clinic from outside of Olmsted County were also reported. This study demonstrated that most of the patients with concurrent MS and IBD in this population had a mild to moderate disability after a median follow up of almost eight years. Later, a cohort and a cross-sectional studies<sup><xref ref-type="bibr" rid="bibr51-1352458512461393">51</xref></sup> were done on a total of 7988 CD and 12,185 UC patients. They were randomly matched with 80,666 controls. In both study designs, the incidence and the prevalence of optic neuritis, demyelination and/or MS were found to be higher in patients with IBD. The association was more pronounced for patients with UC. In the cross-sectional study the odds ratio for being diagnosed with optic neuritis, demyelination, or MS in patients with UC was 1.75 (95% confidence interval (CI) 1.28–2.39), and for patients with CD was 1.54 (95% CI 1.03–2.32). None of the IBD patients was treated with anti-TNF-α agents. An association between UC, and not CD, with MS was also demonstrated in a large population-based study in Manitoba, Canada.<sup><xref ref-type="bibr" rid="bibr52-1352458512461393">52</xref></sup> The study enrolled 4193 CD patients and 3879 UC patients. The authors proposed that the increased risk for having MS in UC patients might be only a chance observation since it was confined to a distinct group of men who were 40–59 years old.</p>
</sec>
<sec id="section7-1352458512461393">
<title>Common hypothesis: genetic susceptibility and environmental factors</title>
<p>Multiple alleles in the major histo-compatibility complex (MHC) appear to contribute to a number of diseases including autoimmune disorders.<sup><xref ref-type="bibr" rid="bibr53-1352458512461393">53</xref></sup> The MHC region harbors several genotypes that either protect or predispose a person to the development of autoimmune diseases.<sup><xref ref-type="bibr" rid="bibr54-1352458512461393">54</xref></sup> It is however challenging to causally link the MHC to MS or other diseases because of the high amount of linkage disequilibrium between segments and the great number of alleles present in some of the MHC genes.<sup><xref ref-type="bibr" rid="bibr54-1352458512461393">54</xref></sup> In IBD, genome-wide association studies demonstrated linkage to the MHC in the IBD3 locus, with a stronger influence on susceptibility to UC than to CD.</p>
<p>Polymorphism in non-MHC genetic susceptibility loci has also been linked to the risk of development of both MS and IBD, as well as other autoimmune disorders.<sup><xref ref-type="bibr" rid="bibr54-1352458512461393">54</xref></sup></p>
<p>Interestingly, both MS and IBD have a north to south geographic gradient in their prevalence.<sup><xref ref-type="bibr" rid="bibr55-1352458512461393">55</xref></sup> This could be attributed to a number of factors. The difference in climates, has led to the suggestion that infections with organisms that survive in colder climates may play a role in the pathogenesis of these autoimmune disorders.<sup><xref ref-type="bibr" rid="bibr55-1352458512461393">55</xref></sup> Another major factor that has been linked to the development of autoimmune diseases, including MS, IBD, rheumatoid arthritis, SLE and type I diabetes, is vitamin D deficiency. Patients with MS as well as those with IBD have been found to have low serum levels of vitamin D<sup><xref ref-type="bibr" rid="bibr56-1352458512461393">56</xref>,<xref ref-type="bibr" rid="bibr57-1352458512461393">57</xref></sup> although the exact cause of this observation in either group is not established and could be multi-factorial.</p>
<p>Similarly, Green et al. found a higher incidence of MS and IBD in populations of higher socioeconomic status.<sup><xref ref-type="bibr" rid="bibr55-1352458512461393">55</xref></sup> Evidence is mounting that helminth infestation could play a regulatory role in the immune system biasing the immune response towards a T-helper-2 cells response, and reducing the risk of developing MS.<sup><xref ref-type="bibr" rid="bibr58-1352458512461393">58</xref></sup> It is difficult to reconcile this theory, however, with the fact that infections may trigger autoimmune diseases through polyclonal lymphocyte activation, antigen mimicry or increased immunogenicity of organ auto-antigens secondary to infection-mediated inflammation.<sup><xref ref-type="bibr" rid="bibr59-1352458512461393">59</xref></sup></p>
<p>There are a number of other environmental and non-environmental factors that have been implicated in the development of MS and IBD, including diet,<sup><xref ref-type="bibr" rid="bibr11-1352458512461393">11</xref>,<xref ref-type="bibr" rid="bibr60-1352458512461393">60</xref></sup> use of oral contraceptives,<sup><xref ref-type="bibr" rid="bibr61-1352458512461393">61</xref>,<xref ref-type="bibr" rid="bibr62-1352458512461393">62</xref></sup> psychological stress<sup><xref ref-type="bibr" rid="bibr63-1352458512461393">63</xref>,<xref ref-type="bibr" rid="bibr64-1352458512461393">64</xref></sup> and cigarette smoking. Except for the latter, the evidence that these are risk factors for MS or IBD is insufficient.<sup><xref ref-type="bibr" rid="bibr11-1352458512461393">11</xref>,<xref ref-type="bibr" rid="bibr65-1352458512461393">65</xref>,<xref ref-type="bibr" rid="bibr66-1352458512461393">66</xref></sup></p>
<p>Last but not least, and as we briefly alluded to above, it is possible that the association between MS and IBD is, at least partially, one of cause and effect. The development of EAE differed remarkably between mice colonized with communal gut microbiota and those which were germ-free. This and other pertinent observations possibly suggest a central role for the gut in the development of immune-mediated diseases. For further details on this subject, the reader is referred to the references.<sup><xref ref-type="bibr" rid="bibr13-1352458512461393">13</xref>,<xref ref-type="bibr" rid="bibr67-1352458512461393">67</xref>,<xref ref-type="bibr" rid="bibr68-1352458512461393">68</xref></sup></p>
</sec>
<sec id="section8-1352458512461393" sec-type="conclusions">
<title>Conclusions</title>
<p>It is highly plausible that IBD patients are at higher risk of developing MS relative to the general population. Shared genetic susceptibility and epidemiological characteristics have been clearly established through a number of studies. The role of the gut in developing and modulating the immune system may explain the cellular/molecular basis of the relationship between the two diseases.</p>
<p>A number of important questions, however, remain unanswered:</p>
<list id="list1-1352458512461393" list-type="order"><list-item><p>Do those patients with IBD really have MS, or do they have a distinct neurological MS-like disease? How many fulfilled criteria for clinically definite MS? How did their MRI studies differ from MS patients without IBD ?</p></list-item>
<list-item><p>Is this a simple association or is it causation? And then, can we call this secondary MS? In other words, can we consider MS or CNS demyelinating events in these patients as an extraintestinal manifestation of IBD or is it just a concurrent illness? If they were extraintestinal manifestations of IBD in these patients, would MS remit if the IBD was cured or was treated to result in remission?</p></list-item>
<list-item><p>What is the real frequency of subclinical bowel disease among MS patients, how many have “leaky gut” syndrome?<sup><xref ref-type="bibr" rid="bibr69-1352458512461393">69</xref>,<xref ref-type="bibr" rid="bibr70-1352458512461393">70</xref></sup></p></list-item>
<list-item><p>Is having subclinical white matter lesions a contraindication to treatment with anti-TNF-α ?</p></list-item></list>
<p>It might be some time before these questions can be answered due to the relative rarity of this combination: however, when resolved, potential therapeutic avenues might open for both diseases.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label><p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
<fn fn-type="conflict">
<label>Conflict of interest</label><p>The authors declare that there are no conflicts of interest.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512461393">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>DH</given-names></name>
<name><surname>Weinshenker</surname><given-names>BG</given-names></name>
<name><surname>Filippi</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Differential diagnosis of suspected multiple sclerosis: a consensus approach</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>1157</fpage>–<lpage>1174</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512461393">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nelson</surname><given-names>J</given-names></name>
<name><surname>Barron</surname><given-names>MM</given-names></name>
<name><surname>Riggs</surname><given-names>JE</given-names></name>
<etal/>
</person-group>. <article-title>Cerebral vasculitis and ulcerative colitis</article-title>. <source>Neurology</source> <year>1986</year>; <volume>36</volume>: <fpage>719</fpage>–<lpage>721</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512461393">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ullrich</surname><given-names>S</given-names></name>
<name><surname>Schinke</surname><given-names>S</given-names></name>
<name><surname>Both</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Refractory central nervous system vasculitis and gastrocnemius myalgia syndrome in Crohn’s disease successfully treated with anti-tumor necrosis factor-alpha antibody</article-title>. <source>Semin Arthritis Rheum</source> <year>2009</year>; <volume>38</volume>: <fpage>337</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512461393">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Metcalf</surname><given-names>M</given-names></name>
<name><surname>Xu</surname><given-names>D</given-names></name>
<name><surname>Okuda</surname><given-names>DT</given-names></name>
<etal/>
</person-group>. <article-title>High-resolution phased-array MRI of the human brain at 7 tesla: initial experience in multiple sclerosis patients</article-title>. <source>J Neuroimaging</source> <year>2010</year>; <volume>20</volume>: <fpage>141</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512461393">
<label>5.</label>
<citation citation-type="journal"><collab>The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group</collab>. <article-title>TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study</article-title>. <source>Neurology</source> <year>1999</year>; <volume>53</volume>: <fpage>457</fpage>–<lpage>465</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512461393">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Oosten</surname><given-names>BW</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<name><surname>Truyen</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2</article-title>. <source>Neurology</source> <year>1996</year>; <volume>47</volume>: <fpage>1531</fpage>–<lpage>1534</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512461393">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sadovnick</surname><given-names>AD</given-names></name>
<name><surname>Paty</surname><given-names>DW</given-names></name>
<name><surname>Yannakoulias</surname><given-names>G</given-names></name>
</person-group> <article-title>Concurrence of multiple sclerosis and inflammatory bowel disease</article-title>. <source>N Engl J Med</source> <year>1989</year>; <volume>321</volume>: <fpage>762</fpage>–<lpage>763</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512461393">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tlaskalova-Hogenova</surname><given-names>H</given-names></name>
<name><surname>Stepankova</surname><given-names>R</given-names></name>
<name><surname>Kozakova</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases</article-title>. <source>Cell Mol Immunol</source> <year>2011</year>; <volume>8</volume>: <fpage>110</fpage>–<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512461393">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Westall</surname><given-names>FC</given-names></name>
</person-group> <article-title>Molecular mimicry revisited: gut bacteria and multiple sclerosis</article-title>. <source>J Clin Microbiol</source> <year>2006</year>; <volume>44</volume>: <fpage>2099</fpage>–<lpage>2104</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512461393">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hill</surname><given-names>DA</given-names></name>
<name><surname>Artis</surname><given-names>D</given-names></name>
</person-group> <article-title>Intestinal bacteria and the regulation of immune cell homeostasis</article-title>. <source>Annu Rev Immunol</source> <year>2010</year>; <volume>28</volume>: <fpage>623</fpage>–<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512461393">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Embry</surname><given-names>AF</given-names></name>
</person-group> <article-title>The multiple factors of multiple sclerosis</article-title>. <source>J Nutr Environ Med</source> <year>2004</year>; <volume>14</volume>: <fpage>307</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512461393">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yacyshyn</surname><given-names>B</given-names></name>
<name><surname>Meddings</surname><given-names>J</given-names></name>
<name><surname>Sadowski</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability</article-title>. <source>Dig Dis Sci</source> <year>1996</year>; <volume>41</volume>: <fpage>2493</fpage>–<lpage>2498</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512461393">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ochoa-Reparaz</surname><given-names>J</given-names></name>
<name><surname>Mielcarz</surname><given-names>DW</given-names></name>
<name><surname>Ditrio</surname><given-names>LE</given-names></name>
<etal/>
</person-group>. <article-title>Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis</article-title>. <source>J Immunol</source> <year>2009</year>; <volume>183</volume>: <fpage>6041</fpage>–<lpage>6050</lpage>.</citation>
</ref>
<ref id="bibr14-1352458512461393">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Panwala</surname><given-names>CM</given-names></name>
<name><surname>Jones</surname><given-names>JC</given-names></name>
<name><surname>Viney</surname><given-names>JL</given-names></name>
</person-group> <article-title>A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis</article-title>. <source>J Immunol</source> <year>1998</year>; <volume>161</volume>: <fpage>5733</fpage>–<lpage>5744</lpage>.</citation>
</ref>
<ref id="bibr15-1352458512461393">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peck</surname><given-names>OC</given-names></name>
<name><surname>Wood</surname><given-names>JD</given-names></name>
</person-group> <article-title>Brain-gut interactions in ulcerative colitis</article-title>. <source>Gastroenterology</source> <year>2000</year>; <volume>118</volume>: <fpage>807</fpage>–<lpage>808</lpage>.</citation>
</ref>
<ref id="bibr16-1352458512461393">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stasi</surname><given-names>C</given-names></name>
<name><surname>Orlandelli</surname><given-names>E</given-names></name>
</person-group> <article-title>Role of the brain-gut axis in the pathophysiology of Crohn’s disease</article-title>. <source>Dig Dis</source> <year>2008</year>; <volume>26</volume>: <fpage>156</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr17-1352458512461393">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sartor</surname><given-names>RB</given-names></name>
</person-group> <article-title>Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases</article-title>. <source>Am J Gastroenterol</source> <year>1997</year>; <volume>92</volume>: <fpage>S5</fpage>–<lpage>S11</lpage>.</citation>
</ref>
<ref id="bibr18-1352458512461393">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Danese</surname><given-names>S</given-names></name>
<name><surname>Semeraro</surname><given-names>S</given-names></name>
<name><surname>Papa</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Extraintestinal manifestations in inflammatory bowel disease</article-title>. <source>World J Gastroenterol</source> <year>2005</year>; <volume>11</volume>: <fpage>7227</fpage>–<lpage>7236</lpage>.</citation>
</ref>
<ref id="bibr19-1352458512461393">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Veloso</surname><given-names>FT</given-names></name>
<name><surname>Carvalho</surname><given-names>J</given-names></name>
<name><surname>Magro</surname><given-names>F</given-names></name>
</person-group> <article-title>Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients</article-title>. <source>J Clin Gastroenterol</source> <year>1996</year>; <volume>23</volume>: <fpage>29</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr20-1352458512461393">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gobbele</surname><given-names>R</given-names></name>
<name><surname>Reith</surname><given-names>W</given-names></name>
<name><surname>Block</surname><given-names>F</given-names></name>
</person-group> [<article-title>Cerebral vasculitis as a concomitant neurological illness in Crohn’s disease</article-title>]. <source>Nervenarzt</source> <year>2000</year>; <volume>71</volume>: <fpage>299</fpage>–<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr21-1352458512461393">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lossos</surname><given-names>A</given-names></name>
<name><surname>River</surname><given-names>Y</given-names></name>
<name><surname>Eliakim</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Neurologic aspects of inflammatory bowel disease</article-title>. <source>Neurology</source> <year>1995</year>;<volume>45</volume>: <fpage>416</fpage>–<lpage>421</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512461393">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Das</surname><given-names>R</given-names></name>
<name><surname>Vasishta</surname><given-names>RK</given-names></name>
<name><surname>Banerjee</surname><given-names>AK</given-names></name>
</person-group> <article-title>Aseptic cerebral venous thrombosis associated with idiopathic ulcerative colitis: a report of two cases</article-title>. <source>Clin Neurol Neurosurg</source> <year>1996</year>; <volume>98</volume>: <fpage>179</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr23-1352458512461393">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calderon</surname><given-names>R</given-names></name>
<name><surname>Cruz-Correa</surname><given-names>MR</given-names></name>
<name><surname>Torres</surname><given-names>EA</given-names></name>
</person-group> <article-title>Cerebral thrombosis associated with active Crohn’s disease</article-title>. <source>P R Health Sci J</source> <year>1998</year>; <volume>17</volume>: <fpage>293</fpage>–<lpage>295</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512461393">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghezzi</surname><given-names>A</given-names></name>
<name><surname>Zaffaroni</surname><given-names>M</given-names></name>
</person-group> <article-title>Neurological manifestations of gastrointestinal disorders, with particular reference to the differential diagnosis of multiple sclerosis</article-title>. <source>Neurol Sci</source> <year>2001</year>; <volume>22</volume>: <fpage>S117</fpage>–<lpage>S122</lpage>.</citation>
</ref>
<ref id="bibr25-1352458512461393">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prescinotto</surname><given-names>R</given-names></name>
<name><surname>Zanini</surname><given-names>RV</given-names></name>
<name><surname>Rapoport</surname><given-names>PB</given-names></name>
<etal/>
</person-group>. <article-title>Autoimmune hearing loss and ulcerative colitis</article-title>. <source>Braz J Otorhinolaryngol</source> <year>2006</year>; <volume>72</volume>: <fpage>572</fpage>.</citation>
</ref>
<ref id="bibr26-1352458512461393">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freilinger</surname><given-names>T</given-names></name>
<name><surname>Riedel</surname><given-names>E</given-names></name>
<name><surname>Holtmannspotter</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Ischemic stroke and peripheral arterial thromboembolism in a patient with Crohn’s disease: a case presentation</article-title>. <source>J Neurol Sci</source> <year>2008</year>; <volume>266</volume>: <fpage>177</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr27-1352458512461393">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>GR</given-names></name>
<name><surname>Teles</surname><given-names>BC</given-names></name>
<name><surname>Brasil</surname><given-names>EF</given-names></name>
<etal/>
</person-group>. <article-title>Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients</article-title>. <source>Inflamm Bowel Dis</source> <year>2008</year>; <volume>14</volume>: <fpage>389</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr28-1352458512461393">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holzer</surname><given-names>K</given-names></name>
<name><surname>Esposito</surname><given-names>L</given-names></name>
<name><surname>Stimmer</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Cerebral vasculitis mimicking migraine with aura in a patient with Crohn’s disease</article-title>. <source>Acta Neurol Belg</source> <year>2009</year>; <volume>109</volume>: <fpage>44</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr29-1352458512461393">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Lau</surname><given-names>LM</given-names></name>
<name><surname>De Vries</surname><given-names>JM</given-names></name>
<name><surname>Van der Woude</surname><given-names>CJ</given-names></name>
<etal/>
</person-group>. <article-title>Acute CNS white matter lesions in patients with inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source> <year>2009</year>; <volume>15</volume>: <fpage>576</fpage>–<lpage>580</lpage>.</citation>
</ref>
<ref id="bibr30-1352458512461393">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agranoff</surname><given-names>D</given-names></name>
<name><surname>Schon</surname><given-names>F</given-names></name>
</person-group> <article-title>Are focal white matter lesions in patients with inflammatory bowel disease linked to multiple sclerosis?</article-title> <source>Lancet</source> <year>1995</year>; <volume>346</volume>: <fpage>190</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr31-1352458512461393">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joshi</surname><given-names>D</given-names></name>
<name><surname>Dickel</surname><given-names>T</given-names></name>
<name><surname>Aga</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Stroke in inflammatory bowel disease: a report of two cases and review of the literature</article-title>. <source>Thromb J</source> <year>2008</year>; <volume>6</volume>: <fpage>2</fpage>.</citation>
</ref>
<ref id="bibr32-1352458512461393">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baumgart</surname><given-names>DC</given-names></name>
<name><surname>Sandborn</surname><given-names>WJ</given-names></name>
</person-group> <article-title>Inflammatory bowel disease: clinical aspects and established and evolving therapies</article-title>. <source>Lancet</source> <year>2007</year>; <volume>369</volume>: <fpage>1641</fpage>–<lpage>1657</lpage>.</citation>
</ref>
<ref id="bibr33-1352458512461393">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burger</surname><given-names>D</given-names></name>
<name><surname>Travis</surname><given-names>S</given-names></name>
</person-group> <article-title>Conventional medical management of inflammatory bowel disease</article-title>. <source>Gastroenterology</source> <year>2011</year>; <volume>140</volume>: <fpage>1827</fpage>–<lpage>1837</lpage></citation>
</ref>
<ref id="bibr34-1352458512461393">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freeman</surname><given-names>HJ</given-names></name>
<name><surname>Flak</surname><given-names>B</given-names></name>
</person-group> <article-title>Demyelination-like syndrome in Crohn’s disease after infliximab therapy</article-title>. <source>Can J Gastroenterol</source> <year>2005</year>; <volume>19</volume>: <fpage>313</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr35-1352458512461393">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>CW</given-names></name>
<name><surname>Weinshenker</surname><given-names>BG</given-names></name>
<name><surname>Sandborn</surname><given-names>WJ</given-names></name>
</person-group> <article-title>Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn’s disease</article-title>. <source>Inflamm Bowel Dis</source> <year>2004</year>; <volume>10</volume>: <fpage>28</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr36-1352458512461393">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>A</given-names></name>
<name><surname>Loes</surname><given-names>DJ</given-names></name>
<name><surname>Bressler</surname><given-names>EL</given-names></name>
</person-group> <article-title>Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy</article-title>. <source>Neurology</source> <year>1995</year>; <volume>45</volume>: <fpage>588</fpage>–<lpage>589</lpage>.</citation>
</ref>
<ref id="bibr37-1352458512461393">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ebner</surname><given-names>F</given-names></name>
<name><surname>Ranner</surname><given-names>G</given-names></name>
<name><surname>Slavc</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>MR findings in methotrexate-induced CNS abnormalities</article-title>. <source>AJR Am J Roentgenol</source> <year>1989</year>; <volume>153</volume>: <fpage>1283</fpage>–<lpage>1288</lpage>.</citation>
</ref>
<ref id="bibr38-1352458512461393">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnett</surname><given-names>HA</given-names></name>
<name><surname>Mason</surname><given-names>J</given-names></name>
<name><surname>Marino</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination</article-title>. <source>Nature Neurosci</source> <year>2001</year>; <volume>4</volume>: <fpage>1116</fpage>–<lpage>1122</lpage>.</citation>
</ref>
<ref id="bibr39-1352458512461393">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barcellos</surname><given-names>LF</given-names></name>
<name><surname>Kamdar</surname><given-names>BB</given-names></name>
<name><surname>Ramsay</surname><given-names>PP</given-names></name>
<etal/>
</person-group>. <article-title>Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study</article-title>. <source>Lancet Neurol</source> <year>2006</year>; <volume>5</volume>: <fpage>924</fpage>–<lpage>931</lpage>.</citation>
</ref>
<ref id="bibr40-1352458512461393">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>NM</given-names></name>
<name><surname>Frisch</surname><given-names>M</given-names></name>
<name><surname>Rostgaard</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>823</fpage>–<lpage>829</lpage>.</citation>
</ref>
<ref id="bibr41-1352458512461393">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramagopalan</surname><given-names>SV</given-names></name>
<name><surname>Dyment</surname><given-names>DA</given-names></name>
<name><surname>Valdar</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Autoimmune disease in families with multiple sclerosis: a population-based study</article-title>. <source>Lancet Neurol</source> <year>2007</year>; <volume>6</volume>: <fpage>604</fpage>–<lpage>610</lpage>.</citation>
</ref>
<ref id="bibr42-1352458512461393">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lees</surname><given-names>CW</given-names></name>
<name><surname>Ali</surname><given-names>A</given-names></name>
<name><surname>Thompson</surname><given-names>AI</given-names></name>
<etal/>
</person-group>. <article-title>The safety profile of anti-TNF therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up</article-title>. <source>Aliment Pharmacol Ther</source> <year>2009</year> <month>Feb</month> <day>1</day>; <volume>29</volume>(<issue>3</issue>): <fpage>286</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr43-1352458512461393">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colombel</surname><given-names>JF</given-names></name>
<name><surname>Loftus</surname><given-names>EV</given-names></name>
<name><surname>Tremaine</surname><given-names>WJ</given-names></name>
<etal/>
</person-group>. <article-title>The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients</article-title>. <source>Gastroenterology</source> <year>2004</year>; <volume>126</volume>: <fpage>19</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr44-1352458512461393">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersen</surname><given-names>NN</given-names></name>
<name><surname>Caspersen</surname><given-names>S</given-names></name>
<name><surname>Jess</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Occurrence of demyelinating diseases after anti-TNFalpha treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study</article-title>. <source>J Crohns Colitis</source> <year>2008</year>; <volume>2</volume>: <fpage>304</fpage>–<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr45-1352458512461393">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geissler</surname><given-names>A</given-names></name>
<name><surname>Andus</surname><given-names>T</given-names></name>
<name><surname>Roth</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Focal white-matter lesions in brain of patients with inflammatory bowel disease</article-title>. <source>Lancet</source> <year>1995</year>; <volume>345</volume>: <fpage>897</fpage>–<lpage>898</lpage>.</citation>
</ref>
<ref id="bibr46-1352458512461393">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hart</surname><given-names>PE</given-names></name>
<name><surname>Gould</surname><given-names>SR</given-names></name>
<name><surname>MacSweeney</surname><given-names>JE</given-names></name>
<etal/>
</person-group>. <article-title>Brain white-matter lesions in inflammatory bowel disease</article-title>. <source>Lancet</source> <year>1998</year>; <volume>351</volume>: <fpage>1558</fpage>.</citation>
</ref>
<ref id="bibr47-1352458512461393">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>M</given-names></name>
<name><surname>Lee</surname><given-names>G</given-names></name>
<name><surname>Kwong</surname><given-names>LN</given-names></name>
<name><surname>Lamont</surname><given-names>S</given-names></name>
<name><surname>Chaves</surname><given-names>C</given-names></name>
</person-group> <article-title>Cerebral white matter lesions in patients with Crohn’s disease</article-title>. <source>J Neuroimaging</source> <year>2012</year> <month>Jan</month>; <volume>22</volume>(<issue>1</issue>): <fpage>38</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr48-1352458512461393">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siva</surname><given-names>A</given-names></name>
<name><surname>Saip</surname><given-names>S</given-names></name>
<name><surname>Altintas</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>918</fpage>–<lpage>927</lpage>.</citation>
</ref>
<ref id="bibr49-1352458512461393">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rang</surname><given-names>EH</given-names></name>
<name><surname>Brooke</surname><given-names>BN</given-names></name>
<name><surname>Hermon-Taylor</surname><given-names>J</given-names></name>
</person-group> <article-title>Association of ulcerative colitis with multiple sclerosis</article-title>. <source>Lancet</source> <year>1982</year>; <volume>2</volume>: <fpage>555</fpage>.</citation>
</ref>
<ref id="bibr50-1352458512461393">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kimura</surname><given-names>K</given-names></name>
<name><surname>Hunter</surname><given-names>SF</given-names></name>
<name><surname>Thollander</surname><given-names>MS</given-names></name>
<etal/>
</person-group>. <article-title>Concurrence of inflammatory bowel disease and multiple sclerosis</article-title>. <source>Mayo Clin Proc</source> <year>2000</year>;<volume>75</volume>:<fpage>802</fpage>–<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr51-1352458512461393">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>G</given-names></name>
<name><surname>Gelfand</surname><given-names>JM</given-names></name>
<name><surname>Lewis</surname><given-names>JD</given-names></name>
</person-group> <article-title>Increased risk for demyelinating diseases in patients with inflammatory bowel disease</article-title>. <source>Gastroenterology</source> <year>2005</year>; <volume>129</volume>: <fpage>819</fpage>–<lpage>826</lpage>.</citation>
</ref>
<ref id="bibr52-1352458512461393">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bernstein</surname><given-names>CN</given-names></name>
<name><surname>Wajda</surname><given-names>A</given-names></name>
<name><surname>Blanchard</surname><given-names>JF</given-names></name>
</person-group> <article-title>The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study</article-title>. <source>Gastroenterology</source> <year>2005</year>;<volume>129</volume>: <fpage>827</fpage>–<lpage>836</lpage>.</citation>
</ref>
<ref id="bibr53-1352458512461393">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fernando</surname><given-names>MM</given-names></name>
<name><surname>Stevens</surname><given-names>CR</given-names></name>
<name><surname>Walsh</surname><given-names>EC</given-names></name>
<etal/>
</person-group>. <article-title>Defining the role of the MHC in autoimmunity: a review and pooled analysis</article-title>. <source>PLoS Genet</source> <year>2008</year>; <volume>4</volume>: <fpage>e1000024</fpage>.</citation>
</ref>
<ref id="bibr54-1352458512461393">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lettre</surname><given-names>G</given-names></name>
<name><surname>Rioux</surname><given-names>JD</given-names></name>
</person-group> <article-title>Autoimmune diseases: insights from genome-wide association studies</article-title>. <source>Hum Mol Genet</source> <year>2008</year>; <volume>17</volume>: <fpage>R116</fpage>–<lpage>R121</lpage>.</citation>
</ref>
<ref id="bibr55-1352458512461393">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Green</surname><given-names>C</given-names></name>
<name><surname>Elliott</surname><given-names>L</given-names></name>
<name><surname>Beaudoin</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues</article-title>. <source>Am J Epidemiol</source> <year>2006</year>; <volume>164</volume>: <fpage>615</fpage>–<lpage>623</lpage>.</citation>
</ref>
<ref id="bibr56-1352458512461393">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pappa</surname><given-names>HM</given-names></name>
<name><surname>Gordon</surname><given-names>CM</given-names></name>
<name><surname>Saslowsky</surname><given-names>TM</given-names></name>
<etal/>
</person-group>. <article-title>Vitamin D status in children and young adults with inflammatory bowel disease</article-title>. <source>Pediatrics</source> <year>2006</year>; <volume>118</volume>: <fpage>1950</fpage>–<lpage>1961</lpage>.</citation>
</ref>
<ref id="bibr57-1352458512461393">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Munger</surname><given-names>KL</given-names></name>
<name><surname>Levin</surname><given-names>LI</given-names></name>
<name><surname>Hollis</surname><given-names>BW</given-names></name>
<etal/>
</person-group>. <article-title>Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis</article-title>. <source>JAMA</source> <year>2006</year>; <volume>296</volume>: <fpage>2832</fpage>–<lpage>2838</lpage>.</citation>
</ref>
<ref id="bibr58-1352458512461393">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elliott</surname><given-names>DE</given-names></name>
<name><surname>Summers</surname><given-names>RW</given-names></name>
<name><surname>Weinstock</surname><given-names>JV</given-names></name>
</person-group> <article-title>Helminths as governors of immune-mediated inflammation</article-title>. <source>Int J Parasitol</source> <year>2007</year>; <volume>37</volume>: <fpage>457</fpage>–<lpage>464</lpage>.</citation>
</ref>
<ref id="bibr59-1352458512461393">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bach</surname><given-names>JF</given-names></name>
</person-group> <article-title>Infections and autoimmune diseases</article-title>. <source>J Autoimmun</source> <year>2005</year>; <volume>25</volume>: <fpage>S74</fpage>–<lpage>S80</lpage>.</citation>
</ref>
<ref id="bibr60-1352458512461393">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hall</surname><given-names>EH</given-names></name>
<name><surname>Crowe</surname><given-names>SE</given-names></name>
</person-group> <article-title>Environmental and lifestyle influences on disorders of the large and small intestine: implications for treatment</article-title>. <source>Dig Dis</source> <year>2011</year>; <volume>29</volume>: <fpage>249</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr61-1352458512461393">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alonso</surname><given-names>A</given-names></name>
<name><surname>Clark</surname><given-names>CJ</given-names></name>
</person-group> <article-title>Oral contraceptives and the risk of multiple sclerosis: a review of the epidemiologic evidence</article-title>. <source>J Neurol Sci</source> <year>2009</year>; <volume>286</volume>: <fpage>73</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr62-1352458512461393">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>SC</given-names></name>
<name><surname>Woodrow</surname><given-names>S</given-names></name>
<name><surname>Patel</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Role of genetic and environmental factors in British twins with inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source> <year>2012</year> <month>Apr</month>; <volume>18</volume>(<issue>4</issue>): <fpage>725</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr63-1352458512461393">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riise</surname><given-names>T</given-names></name>
<name><surname>Mohr</surname><given-names>DC</given-names></name>
<name><surname>Munger</surname><given-names>KL</given-names></name>
<etal/>
</person-group>. <article-title>Stress and the risk of multiple sclerosis</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>:<fpage>1866</fpage>–<lpage>1871</lpage>.</citation>
</ref>
<ref id="bibr64-1352458512461393">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Norgard</surname><given-names>B</given-names></name>
<name><surname>Precht</surname><given-names>DH</given-names></name>
<etal/>
</person-group>. <article-title>Psychological stress and inflammatory bowel disease: a follow-up study in parents who lost a child in Denmark</article-title>. <source>Am J Gastroenterol</source> <year>2004</year>; <volume>99</volume>:<fpage>1129</fpage>–<lpage>1133</lpage>.</citation>
</ref>
<ref id="bibr65-1352458512461393">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hedstrom</surname><given-names>AK</given-names></name>
<name><surname>Baarnhielm</surname><given-names>M</given-names></name>
<name><surname>Olsson</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis</article-title>. <source>Neurology</source> <year>2009</year>; <volume>73</volume>: <fpage>696</fpage>–<lpage>701</lpage>.</citation>
</ref>
<ref id="bibr66-1352458512461393">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lakatos</surname><given-names>PL</given-names></name>
</person-group> <article-title>Environmental factors affecting inflammatory bowel disease: have we made progress?</article-title> <source>Dig Dis</source> <year>2009</year>; <volume>27</volume>: <fpage>215</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr67-1352458512461393">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>YK</given-names></name>
<name><surname>Menezes</surname><given-names>JS</given-names></name>
<name><surname>Umesaki</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2011</year>; <volume>108</volume>: <fpage>S4615</fpage>–<lpage>S4622</lpage>.</citation>
</ref>
<ref id="bibr68-1352458512461393">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berer</surname><given-names>K</given-names></name>
<name><surname>Mues</surname><given-names>M</given-names></name>
<name><surname>Koutrolos</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination</article-title>. <source>Nature</source> <year>2011</year>; <volume>479</volume>:<fpage>538</fpage>–<lpage>541</lpage>.</citation>
</ref>
<ref id="bibr69-1352458512461393">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sakata</surname><given-names>T</given-names></name>
<name><surname>Niwa</surname><given-names>Y</given-names></name>
<name><surname>Goto</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Asymptomatic inflammatory bowel disease with special reference to ulcerative colitis in apparently healthy persons</article-title>. <source>Am J Gastroenterol</source> <year>2001</year>; <volume>96</volume>:<fpage>735</fpage>–<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr70-1352458512461393">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Howarth</surname><given-names>GF</given-names></name>
<name><surname>Robinson</surname><given-names>MH</given-names></name>
<name><surname>Jenkins</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>High prevalence of undetected ulcerative colitis: data from the Nottingham fecal occult blood screening trial</article-title>. <source>Am J Gastroenterol</source> <year>2002</year>; <volume>97</volume>: <fpage>690</fpage>–<lpage>694</lpage>.</citation>
</ref></ref-list>
</back>
</article>